-
A Study to Identify Biomarkers of Spinal Muscular Atrophy in Spinraza-Treated Patients
Rochester, MN; La Crosse, WI
The purpose of this study is to identify biomarkers of spinal muscular atrophy in Spinraza-treated patients.
-
Long-Term Follow-Up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
Rochester, MN
A multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death.
-
A Study to Evaluate Pluripotent Stem Cell Models for Spinal Muscular Atrophy (SMA) Patients
Rochester, MN; La Crosse, WI; Jacksonville, FL
The purpose of this study is to perform RNA sequencing on induced pluripotent stem cells (iPSC). By comparing the gene expression of motor neurons derived from iPSC cells of phenotypically discordant Spinal Muscular Atrophy (SMA) sibling pairs and individual cases of SMA, we hope to identify potential protective gene modifiers of SMA. Identifying protective gene modifiers will increase our understanding of the molecular pathogenesis of SMA.
-
Hirayama Disease
Rochester, MN
The purpose of this study is to determine the long-term progression and outcomes in patients who have the diagnosis of Hirayama disease.
-
Gene Editing Research With a Patient Centered Approach
Jacksonville, FL; Rochester, MN
This is an interview study to understand the views of people with the lived experience of 10 different genetic conditions on gene modification therapies, and specifically on prenatal gene editing. Prenatal gene editing is not happening now, but it is possible that prenatal gene editing will be available in the next few years, at least in a research setting, and we want to know your thoughts about the direction this technology is going. We to hope speak with many different stakeholders (patients and their families, clinicians, scientists) with diverse perspectives to understand values and priorities for prenatal gene ...